Skip to main content

Hydroxyurea Use in Patients with Sickle Cell Anemia

Basic Details
Date Posted
Status
Complete
Medical Product
hydroxyurea
Health Outcome(s)
sickle cell anemia
use by indication
Description

The purpose of this request was to characterize hydroxyurea use among members with sickle cell anemia (SCA). Data from January 1, 2000 to September 30, 2015 from 17 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in these reports. This request was distributed on February 28, 2018. This request contains two reports.

Report 1 estimated the number patients with SCA, the number of SCA patients who were dispensed hydroxyurea, and the average number of hospitalizations and emergency department visits per person-year among those patients in the SDD. 

Report 2 examines utilization patterns of hydroxyurea among patients with SCA in the SDD. 

Deliverables (2)
Sentinel Modular Program Report: Hydroxyurea Use in Patients with Sickle Cell Anemia, Report 1 Sentinel Modular Program Report: Hydroxyurea Use in Patients with Sickle Cell Anemia, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - September 30, 2015
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Hydroxyurea & Use by Indication
Sentinel Drug Analysis: Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis
Presentation: Hydroxyurea Utilization Patterns Among Sickle Cell Disease Patients in the United States, US FDA Sentinel Database